Highest-materiality recent filing
Neurocrine completes $2.9B acquisition of Soleno Therapeutics, adds VYKAT XR for Prader-Willi
Tender offer accepted 46.4M shares (88.9% of Soleno) at $53/sh cash; total equity value ~$2.9B.
Net product sales of $811.0M in Q1 2026, a 44% increase year-over-year, led by INGREZZA ($656.9M) and CRENESSITY ($153.3M).
Neurocrine to acquire Soleno Therapeutics for $53.00 per share in cash
Tender offer for all Soleno shares at $53.00 cash each; no financing condition.
Neurocrine reports Q4 2025 revenue $805.5M, EPS $1.48 GAAP; guides INGREZZA 2026 sales $2.7-2.8B
Q4 total net product sales $798.3M (+29% YoY); full year $2.83B (+22% YoY).
Neurocrine extends former CMO Eiry Roberts as Strategic Advisor through Dec 31, 2026
Roberts, former CMO, transitioned to Strategic Advisor effective June 2, 2025; term extended to Dec 31, 2026 (Amended Employment Agreement).
Neurocrine Q3 net product sales $790M (+28% YoY); INGREZZA $687M (+12%); CRENESSITY $98M
GAAP EPS $2.04 (diluted) vs $1.24 YoY; Non-GAAP EPS $2.17 vs $1.81; net income $209.5M.
Neurocrine Biosciences Q2 2025: Revenue $687.5M up 16.5% YoY; valbenazine Phase 3 schizophrenia miss
Total revenue $687.5M; INGREZZA $624.4M (+8% YoY), CRENESSITY $53.2M (launch year).
Neurocrine CMO Eiry Roberts to step down; Sanjay Keswani named successor June 2, 2025
Dr. Eiry Roberts transitions from CMO to Strategic Advisor to the CEO, effective June 2, 2025 through Dec 31, 2025.
Neurocrine holds 2025 annual meeting; shareholders approve new equity plan and amended ESPP
Four Class II directors elected for three-year terms expiring 2028: Kyle Gano, Richard Pops, Shalini Sharp, Stephen Sherwin (each >72M votes).
Sanjay Keswani, M.D. will succeed Eiry W. Roberts, M.D. as the Chief Medical Officer of the Company, effective June 2, 2025.
Sanjay Keswani, M.D. will succeed Eiry W. Roberts, M.D. as the Chief Medical Officer of the Company, effective June 2, 2025.
Max materiality 0.90 · Median 0.75 · Most common event earnings